思路迪醫藥股份：二零二四年年報.pdf

1、2024ANNUAL REPORT年度報告Contents目錄2Definitions釋義8Corporate Information公司資料11Chairmans Statement董事長致辭14Financial Summary財務概要15Management Discussion and Analysis管理層討論及分析48Biographies of Directors and Senior Management董事和高級管理層履歷59Corporate Governance Report企業管治報告81Report of Directors董事會報告114Environmental,

2、Social and Governance Report環境、社會及管治報告193Independent Auditors Report獨立核數師報告201Consolidated Statements of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益202Consolidated Statement of Financial Position綜合財務狀況表204Consolidated Statement of Changes in Equity綜合權益變動表206Consolidated Statement of Cas

3、h Flows綜合現金流量表209Notes to Financial Statements財務報表附註23D Medicines Inc.Annual Report 2024Definitions釋義 “恩維達”envafolimab(brand name:ENWEIDA,恩維達),a subcutaneously-injectable PD-L1 inhibitor for the treatment of tumor-agnostic indication恩維達恩沃利單抗（品牌名：恩維達）是一款用於治療泛瘤種的皮下注射PD-L1抑制劑“3DMed Beijing”3D Medicines

4、(Beijing)Co.,Ltd.*(思路迪（北京）醫藥科技有限公司)思路迪北京“3DMed Hong Kong”3D Medicines(Hong Kong)Co.,Limited(思路迪醫藥科技（香港）有限公司)思路迪香港“3DMed Qingdao”3D Medicines(Qingdao)Co.,Ltd.*(思路迪醫藥（青島）有限公司)思路迪青島“3DMed Shanghai”3DMed Shanghai Pharmaceutical Technology Co.,Ltd.*(思路迪（上海）醫藥科技有限公司)思路迪上海“3DMed Sichuan”Sichuan 3DMed-Alpha

5、mab Co.,Ltd.*(四川思路康瑞藥業有限公司)四川思路康瑞“3DMed Xuzhou”Xuzhou 3D Medicines Pharmaceutical Co.,Ltd.*(徐州思路迪藥業有限公司)思路迪徐州“3D Medicines”3D Medicines Biotechnology(Shanghai)Co.,Ltd.*(思路迪生物醫藥（上海）有限公司)思路迪醫藥“AGM”the annual general meeting of the Company to be held on Monday,June 30,2025股東週年大會2025年6月30日（星期一）舉行本公司股東週年

6、大會“Alphamab Group”Alphamab Oncology(康寧傑瑞生物製藥),an exempted company with limited liability incorporated under the laws of the Cayman Islands on March 28,2018 and listed on the Stock Exchange(stock code:9966),and its subsidiaries,each of which is an Independent Third Party康寧傑瑞集團康寧傑瑞生物製藥，一間於2018年3月28日根據